Identification of Novel CB2 Ligands through Virtual Screening and In Vitro Evaluation

Abstract

Cannabinoid receptor type 2 (CB2) is a very promising therapeutic target for a variety of potential indications. However, despite the existence of multiple high affinity CB2 ligands, none have yet been approved as a drug. Therefore, it would be beneficial to explore new chemotypes of CB2 ligands. The recent elucidation of CB2 tertiary structure allows for rational hit identification with structure-based (SB) methods. In this study, we established a virtual screening workflow based on SB techniques augmented with ligand-based ones, including molecular docking, MM–GBSA binding energy calculations, pharmacophore screening, and QSAR. We screened nearly 7 million drug-like, commercially available compounds. We selected 16 molecules for in vitro evaluation and identified two novel, selective CB2 antagonists with K i values of 65 and 210 nM. Both compounds are structurally diverse from CB2 ligands known to date. The established virtual screening protocol may prove useful for hit identification for CB2 and similar molecular targets. The two novel CB2 ligands provide a desired starting point for future optimization and development of potential drugs.

GC–MS analysis of phytoconstituents from Kigelia africana (Lam.) Benth., and molecular docking interactions of bioactive molecules with target Penicillin-Binding Protein 2 (PBP2)

“…5 & Table 3. According to Ogbodo et al, 2023, reported that 6-hydroxyluteolin had a one of better interacts with potential inhibitors targeting cdk1 in colorectal cancer 20 .…”

Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease

“…However, the solution of the crystal structure for the CB2 receptor (61) has enabled rational drug design approaches (62,63) which have the potential to provide candidate drug molecules that could be tested in the clinic in the near future.…”